GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (STU:9UA) » Definitions » 9-Day RSI

NervGen Pharma (STU:9UA) 9-Day RSI : 52.53 (As of Dec. 15, 2024)


View and export this data going back to 2024. Start your Free Trial

What is NervGen Pharma 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-12-15), NervGen Pharma's 9-Day RSI is 52.53.

The industry rank for NervGen Pharma's 9-Day RSI or its related term are showing as below:

STU:9UA's 9-Day RSI is ranked worse than
80.45% of 1524 companies
in the Biotechnology industry
Industry Median: 43.16 vs STU:9UA: 52.53

Competitive Comparison of NervGen Pharma's 9-Day RSI

For the Biotechnology subindustry, NervGen Pharma's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NervGen Pharma's 9-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's 9-Day RSI falls into.



NervGen Pharma  (STU:9UA) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NervGen Pharma  (STU:9UA) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


NervGen Pharma 9-Day RSI Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


NervGen Pharma Business Description

Comparable Companies
Traded in Other Exchanges
Address
112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.

NervGen Pharma Headlines

No Headlines